Cargando…
Eplerenone: The Multifaceted Drug in Cardiovascular Pharmacology
Conventionally, rennin–angiotensin–aldosterone system (RAAS) inhibition has focused on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers and angiotensin receptor-neprilysin inhibitors (ARNI) are the latest addition to this armamentarium. However, mineralocorticoid recepto...
Autores principales: | Pradhan, Akshyaya, Vohra, Shaweta, Sethi, Rishi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909067/ https://www.ncbi.nlm.nih.gov/pubmed/33679083 http://dx.doi.org/10.4103/jpbs.JPBS_338_19 |
Ejemplares similares
-
COVID-19 and Cardiovascular Diseases: Challenges and Solutions
por: Sharma, Prachi, et al.
Publicado: (2021) -
Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives
por: Pradhan, Akshyaya, et al.
Publicado: (2020) -
Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019) -
Coronavirus and cardiovascular manifestations- getting to the heart of the matter
por: Bhandari, Monika, et al.
Publicado: (2021) -
Fimasartan: A new armament to fight hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)